Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma

被引:0
|
作者
Gross, N [1 ]
Balmas, K
Brognara, CB
Tschopp, J
机构
[1] CHU Vaudois, Univ Hosp, Oncohematol Unit, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 2001年 / 36卷 / 01期
关键词
neuroblastoma; Fas receptor; apoptosis;
D O I
10.1002/1096-911X(20010101)36:1<111::AID-MPO1026>3.0.CO;2-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Procedure. To determine the possible role of Fas/FasL system in the particularly heterogeneous behaviour of neuroblastoma d(NB), we have measured the functional expression of Fas and its ligand, FasL, in primary neuroblastoma samples and cell lines by immunohistochemistry and flow cytometry. Results. Our results reveal that while Fas expression is associated with low stage and more mature tumors, heterogeneous FasL expression was mostly detected in high stage tumors, with-our apparent correlation to MYCN amplification. Flow cytometric analysis of cell lines demonstrated a high expression of Fas in epithelial-type, HLA class I positive cell lines, which was lost upon activation with phorbol esters. In contrast, Fas ligand was detected in only a small subset of cell lines. Conclusions. In some cell lines, cytotoxic assays revealed the ability of NB-associated Fas receptor to transduce an apoptotic signal upon triggering. The pattern of functional Fas/FasL expression in tumours and cell lines suggests that this system may be involved in the evasion of highly malignant neuroblastoma cells to host immune response. Med. Pediatr. Oncol. 36:111-114, 2001. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:111 / 114
页数:4
相关论文
共 50 条
  • [1] Expression of Fas (CD95/APO-1) and Fas Ligand (FasL) in Experimentally-Induced Acute Pancreatitis
    Pardalis, Vassilios
    Palli, Eleni
    Lambropoulou, Maria
    Tsigalou, Christina
    Anagnostoulis, Stavros
    Garoufalis, Grigorios
    Bolanaki, Helen
    Simopoulos, Constantinos
    Karayiannakis, Anastasios J.
    [J]. JOURNAL OF INVESTIGATIVE SURGERY, 2014, 27 (02) : 65 - 72
  • [2] FasL-Fas/APO-1(CD95)系统
    孙长凯
    鞠躬
    [J]. 生理科学进展, 1997, (02) : 42 - 44
  • [3] Characterization of Fas (Apo-1, CD95)-Fas ligand interaction
    Schneider, P
    Bodmer, JL
    Holler, N
    Mattmann, C
    Scuderi, P
    Terskikh, A
    Peitsch, MC
    Tschopp, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) : 18827 - 18833
  • [4] Fas (CD95/Apo-1)/Fas Ligand Expression in Neonates with Pontosubicular Neuron Necrosis
    Frank K H Van Landeghem
    Ursula Felderhoff-Mueser
    Axel Moysich
    Christine Stadelmann
    Michael Obladen
    Wolfgang Brück
    Christoph Bührer
    [J]. Pediatric Research, 2002, 51 : 129 - 135
  • [5] Fas (CD95/Apo-1)/Fas ligand expression in neonates with pontosubicular neuron necrosis
    Van Landeghem, FKH
    Felderhoff-Mueser, U
    Moysich, A
    Stadelmann, C
    Obladen, M
    Brück, W
    Bührer, C
    [J]. PEDIATRIC RESEARCH, 2002, 51 (02) : 129 - 135
  • [6] Fas (CD95, Apo-1) Ligand Gene Transfer
    Salah-Eddine Lamhamedi-Cherradi
    Youhai Chen
    [J]. Journal of Clinical Immunology, 2001, 21 : 24 - 29
  • [7] Fas (CD95, Apo-1) ligand gene transfer
    Lamhamedi-Cherradi, SE
    Chen, YH
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (01) : 24 - 29
  • [8] Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
    Nozawa, K
    Kayagaki, N
    Tokano, Y
    Yagita, H
    Okumura, K
    Hasimoto, H
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (06): : 1126 - 1129
  • [9] Fas/APO-1 (CD95) expression in myelodysplastic syndromes
    Lepelley, P
    Grardel, N
    Erny, O
    Iaru, T
    Obein, V
    Cosson, A
    Fenaux, P
    [J]. LEUKEMIA & LYMPHOMA, 1998, 30 (3-4) : 307 - 312
  • [10] Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack
    O'Connell, J
    Bennett, MW
    O'Sullivan, GC
    Collins, JK
    Shanahan, F
    [J]. DISEASES OF THE ESOPHAGUS, 1999, 12 (02): : 83 - 89